BACKGROUND: Alloimmunization to minor red blood cell (RBC) antigens occurs commonly in sickle cell disease (SCD). Patients with alloimmunization demonstrate increased risk for new alloantibody formation with subsequent transfusion. Alloimmunization to human leukocyte antigens (HLA) can occur with RBC transfusion and may result in graft rejection during stem cell or organ transplantation. The prevalence and risk factors for HLA alloimmunization in multiply transfused pediatric SCD patients are unknown. PROCEDURE: A cross-sectional study of HLA alloimmunization in SCD patients aged 3-21 years with a history of >or=3 RBC transfusions was performed to test the hypothesis that HLA alloimmunization is associated with RBC alloimmunization. Antibodies to class I and class II HLA were measured by Flow Panel Reactive Antibody (FlowPRA). RESULTS: Seventy-three SCD patients (30 with RBC antibodies) were tested. HLA antibodies were detected in 25/73 (34%) patients; class I HLA antibodies occurred in 24/73 (33%) and class II HLA antibodies occurred in 3 (4%). Among patients with RBC antibodies, 16/30 (53%) had HLA antibodies, while 9/43 (21%) patients without RBC antibodies had HLA antibodies (OR 4.32 [1.6-12.1]). In a multivariate analysis, antibodies to RBC antigens were an independent predictor of HLA alloimmunization (P = 0.041). The association of RBC and HLA immunization was strongest among patients with no history of chronic transfusion therapy. CONCLUSIONS: This analysis is the first description of HLA alloimmunization in pediatric SCD patients who receive primarily leukoreduced RBC transfusions and demonstrates that HLA alloimmunization tendency is associated with antibodies to RBC antigens.
BACKGROUND: Alloimmunization to minor red blood cell (RBC) antigens occurs commonly in sickle cell disease (SCD). Patients with alloimmunization demonstrate increased risk for new alloantibody formation with subsequent transfusion. Alloimmunization to human leukocyte antigens (HLA) can occur with RBC transfusion and may result in graft rejection during stem cell or organ transplantation. The prevalence and risk factors for HLA alloimmunization in multiply transfused pediatric SCDpatients are unknown. PROCEDURE: A cross-sectional study of HLA alloimmunization in SCDpatients aged 3-21 years with a history of >or=3 RBC transfusions was performed to test the hypothesis that HLA alloimmunization is associated with RBC alloimmunization. Antibodies to class I and class II HLA were measured by Flow Panel Reactive Antibody (FlowPRA). RESULTS: Seventy-three SCDpatients (30 with RBC antibodies) were tested. HLA antibodies were detected in 25/73 (34%) patients; class I HLA antibodies occurred in 24/73 (33%) and class II HLA antibodies occurred in 3 (4%). Among patients with RBC antibodies, 16/30 (53%) had HLA antibodies, while 9/43 (21%) patients without RBC antibodies had HLA antibodies (OR 4.32 [1.6-12.1]). In a multivariate analysis, antibodies to RBC antigens were an independent predictor of HLA alloimmunization (P = 0.041). The association of RBC and HLA immunization was strongest among patients with no history of chronic transfusion therapy. CONCLUSIONS: This analysis is the first description of HLA alloimmunization in pediatric SCDpatients who receive primarily leukoreduced RBC transfusions and demonstrates that HLA alloimmunization tendency is associated with antibodies to RBC antigens.
Authors: Stephen Spellman; Robert Bray; Sandra Rosen-Bronson; Michael Haagenson; John Klein; Susan Flesch; Cynthia Vierra-Green; Claudio Anasetti Journal: Blood Date: 2010-01-20 Impact factor: 22.113
Authors: Darrell J Triulzi; Steven Kleinman; Ram M Kakaiya; Michael P Busch; Philip J Norris; Whitney R Steele; Simone A Glynn; Christopher D Hillyer; Patricia Carey; Jerome L Gottschall; Edward L Murphy; Jorge A Rios; Paul M Ness; David J Wright; Danielle Carrick; George B Schreiber Journal: Transfusion Date: 2009-05-18 Impact factor: 3.157
Authors: Marianne E McPherson; Alan R Anderson; Ann E Haight; Paula Jessup; Marta-Inés Castillejo; Christopher D Hillyer; Cassandra D Josephson Journal: Transfusion Date: 2009-05-11 Impact factor: 3.157
Authors: Jeanne E Hendrickson; Traci E Chadwick; John D Roback; Christopher D Hillyer; James C Zimring Journal: Blood Date: 2007-06-25 Impact factor: 22.113
Authors: Jeanne E Hendrickson; Natia Saakadze; Chantel M Cadwell; Jason W Upton; Edward S Mocarski; Christopher D Hillyer; James C Zimring Journal: Transfusion Date: 2009-08 Impact factor: 3.157
Authors: Naynesh R Kamani; Mark C Walters; Shelly Carter; Victor Aquino; Joel A Brochstein; Sonali Chaudhury; Mary Eapen; Brian M Freed; Michael Grimley; John E Levine; Brent Logan; Theodore Moore; Julie Panepinto; Suhag Parikh; Michael A Pulsipher; Jane Sande; Kirk R Schultz; Stephen Spellman; Shalini Shenoy Journal: Biol Blood Marrow Transplant Date: 2012-02-16 Impact factor: 5.742
Authors: Robert S Nickel; Jeanne E Hendrickson; Marianne M Yee; Robert A Bray; Howard M Gebel; Leslie S Kean; David B Miklos; John T Horan Journal: Br J Haematol Date: 2015-04-19 Impact factor: 6.998
Authors: John Horan; Tao Wang; Michael Haagenson; Stephen R Spellman; Jason Dehn; Mary Eapen; Haydar Frangoul; Vikas Gupta; Gregory A Hale; Carolyn K Hurley; Susana Marino; Machteld Oudshoorn; Vijay Reddy; Peter Shaw; Stephanie J Lee; Ann Woolfrey Journal: Blood Date: 2012-07-24 Impact factor: 22.113
Authors: Karen Quillen; Consuelito Medrano; Sharon Adams; Brett Peterson; Julia Hackett; Susan F Leitman; Harvey G Klein; David F Stroncek Journal: Transfusion Date: 2010-09-16 Impact factor: 3.157
Authors: Antony Aston; Rebecca Cardigan; Saber Bashir; Susan Proffitt; Helen New; Colin Brown; Ri Liesner; Sylvia Hennem; Helen Nulty; Olivia Shaw; Robert Vaughan; Jon Jin Kim; Lesley Rees Journal: Pediatr Nephrol Date: 2014-04-29 Impact factor: 3.714
Authors: Jeremy Ryan A Peña; Susan L Saidman; Timothy C Girouard; Erin Meister; Walter H Dzik; Robert S Makar Journal: Am J Hematol Date: 2014-06-19 Impact factor: 10.047